Exogenous expression of HER2 was reported to be associated with reduced sensitivity to third-generation EGFR-TKIs in EGFRM NSCLC PC9 cells [20], indicating that HER2 activity underlies the resistance of EGFRM NSCLC cells to EGFR-TKIs. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.